- Home
- VALN vs SANA Comparison
VALN vs SANA Comparison
Compare VALN & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- SANA
- Stock Information
- Founded
- VALN 2012
- SANA 2018
- Country
- VALN France
- SANA United States
- Employees
- VALN N/A
- SANA N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- SANA Medicinal Chemicals and Botanical Products
- Sector
- VALN Health Care
- SANA Health Care
- Exchange
- VALN Nasdaq
- SANA Nasdaq
- Market Cap
- VALN 820.0M
- SANA 983.4M
- IPO Year
- VALN 2021
- SANA 2021
- Fundamental
- Price
- VALN $9.00
- SANA $4.08
- Analyst Decision
- VALN Strong Buy
- SANA Strong Buy
- Analyst Count
- VALN 4
- SANA 7
- Target Price
- VALN $15.75
- SANA $8.00
- AVG Volume (30 Days)
- VALN 26.9K
- SANA 6.8M
- Earning Date
- VALN 11-20-2025
- SANA 11-11-2025
- Dividend Yield
- VALN N/A
- SANA N/A
- EPS Growth
- VALN N/A
- SANA N/A
- EPS
- VALN N/A
- SANA N/A
- Revenue
- VALN $230,566,060.00
- SANA N/A
- Revenue This Year
- VALN $6.86
- SANA N/A
- Revenue Next Year
- VALN $11.85
- SANA N/A
- P/E Ratio
- VALN N/A
- SANA N/A
- Revenue Growth
- VALN 25.47
- SANA N/A
- 52 Week Low
- VALN $3.62
- SANA $1.26
- 52 Week High
- VALN $12.25
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- VALN 36.23
- SANA 41.21
- Support Level
- VALN $9.01
- SANA $5.12
- Resistance Level
- VALN $9.28
- SANA $5.00
- Average True Range (ATR)
- VALN 0.22
- SANA 0.43
- MACD
- VALN -0.11
- SANA -0.21
- Stochastic Oscillator
- VALN 8.75
- SANA 1.62
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.